keine Finanzberatung

INCY · Incyte

Commercial-stage biotech built on the Jakafi blood-cancer franchise

Risiko 6/10 · MODERATE-HIGH RISK · patent-cliff biotech · $126.75 ▼ 0.98%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $126.75
  • Market cap $25.7B
  • P/E (ttm) 16.15
  • Div yield none
  • 52-wk range $81.09 – $132.60
  • Index rank #400 / —

Wichtigste Risiken

  • Jakafi patent cliff guts the revenue base (Shareholders) — HIGH
  • New launches ramp slower than the hole opens (Shareholders) — HIGH
  • Pipeline readouts disappoint (Shareholders) — MED
  • Steady insider selling into the strength (Shareholders) — MED

Fazit

Rare thing: a biotech with real earnings and a clean balance sheet — but the clock on its main drug is running, and the multiple says the market isn't sure the replacements arrive in time.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.